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Ataxia-telangiectasia (A-T) is an autosomal recessive disorder involving cerebellar degeneration, immunodefi-
ciency, chromosomal instability, radiosensitivity and cancer predisposition. The responsible gene, ATM, was
recently identified by positional cloning and found to encode a putative 350 kDa protein with a PI 3-kinase-like
domain, presumably involved in mediating cell cycle arrest in response to radiation-induced DNA damage. The
nature and location of A-T mutations should provide insight into the function of the ATM protein and the molecular
basis of this pleiotropic disease. Of 44 A-T mutations identified by us to date, 39 (89%) are expected to inactivate
the ATM protein by truncating it, by abolishing correct initiation or termination of translation, or by deleting large
segments. Additional mutations are four smaller in-frame deletions and insertions, and one substitution of a
highly conserved amino acid at the PI 3-kinase domain. The emerging profile of mutations causing A-T is thus
dominated by those expected to completely inactivate the ATM protein. ATM mutations with milder effects may
result in phenotypes related, but not identical, to A-T.
INTRODUCTION
Ataxia-telangiectasia (A-T) is a highly pleiotropic disorder inherited
in an autosomal recessive manner, with an average worldwide
frequency of 1:40 000–1:100 000 live births (see refs 1–3 for recent
reviews). Cerebellar ataxia resulting from gradual loss of the
Purkinje cells in the cerebellum is usually the first clinical sign, and
leads to progressive neuromotor deterioration. Its co-occurrence
with telangiectases (dilated blood vessels) in the conjunctivae and
occasionally on the facial skin—the second early hallmark of the
disease—usually establishes the differential diagnosis of A-T from
other cerebellar ataxias. Additional characteristics of this disorder
are cellular and humoral immunodeficiency, thymic and ovarian
degeneration, growth retardation, occasional endocrine abnorma-
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lities, profound predisposition to lymphoreticular malignancies, and
acute sensitivity to ionizing radiation. A-T heterozygotes are
moderately cancer prone, and cultured cells from these individuals
are moderately radiosensitive.
The cellular phenotype of A-T includes reduced life span of
cultured cells, chromosomal instability, hypersensitivity to ioniz-
ing radiation and radiomimetic chemicals, and defective check-
points at the G1, S and G2 phases of the cell cycle (2–5). The G1
and G2 checkpoint defects are evident as reduced delay in cell
cycle progression following treatment with ionizing radiation or
radiomimetic chemicals (5), while the rise in the p53 protein level
usually associated in normal cells with radiation-induced G1
arrest is delayed in A-T cells (6,7). The defective checkpoint at
the S phase is readily observed as radioresistant DNA synthesis
(RDS) (4). Cellular sensitivity to these DNA damaging agents
and RDS are usually considered an integral part of the A-T
phenotype.
Although these clinical and cellular features are considered
common to all ‘classical’ A-T patients, variations have been
noted. Milder forms of the disease with later onset, slower clinical
progression, reduced radiosensitivity and occasional absence of
RDS have been described in several ethnic groups (8–11).
Additional phenotypic variability possibly related to A-T is
suggested by several disorders that show ‘partial A-T phenotype’
with varying combinations of ataxia, immunodeficiency and
chromosomal instability without telangiectases (12–16). Still,
other disorders display the A-T phenotype and additional
features; most notable is the Nijmegen breakage syndrome that
combines A-T features with microcephaly, sometimes with
mental retardation, but without telangiectases (17).
The A-T gene was mapped to chromosome 11q22–23 (18), and
recently cloned in our laboratory using positional cloning and
designated ATM (19,20). This gene spans about 150 kb of
genomic DNA and produces a 13 kb transcript. The predicted 350
kDa protein has a carboxy terminal region of 350 amino acids
which shows strong similarity to the catalytic domain of the p110
subunit of phosphatidylinositol 3-kinase (PI 3-kinase) (19,20).
This protein is similar to several large proteins in various species
that contain PI 3-kinase-like domains at their carboxy termini,
and are involved in DNA damage processing and cell cycle
control. Among these proteins are TEL1p and MEC1p in budding
yeast, rad3p in fission yeast, the TOR proteins in yeast and their
mammalian counterpart, FRAP (RAFT1), mei-41 in Drosophila
melanogaster, and the catalytic subunit of DNA-dependent
protein kinase (DNA-PKCS) in mammals. Mutations in the genes
encoding these proteins result in a variety of phenotypes that
share features with A-T, such as radiosensitivity, chromosomal
instability, telomere shortening, and defective cell cycle check-
points (reviewed in refs 20,21). A possible working model for the
ATM protein’s function is DNA-PK, a serine/threonine protein
kinase that is activated in vitro by DNA double-strand breaks and
responds by phosphorylating several regulatory proteins (22).
The ATM protein may be responsible for conveying a signal
evoked by a specific DNA damage to various checkpoint
systems, possibly via lipid or protein phosphorylation. Elucidating
the nature of the mutations responsible for A-T should give insight
into the molecular and physiological bases of the disease. In our
search for ATM mutations in A-T patients from a variety of ethnic
populations, we report here the unique profile of these mutations.
Figure 1. Detection of large deletions in the ATM transcript in three A-T
patients (Table 1). RT-PCR products obtained from control (1) and patient (2)
RNAs using primers flanking the deletions were separated on a 1.2% agarose
gel. (A) Patient AT12RM showing homozygous deletion of 403 nt; (B)
AT21RM, a patient homozygous for a 90 nt deletion; (C) AT13BER, a patient
heterozygous for a 159 nt deletion. The minor band of intermediate size
represents a heteroduplex of normal and mutant strands typically observed in
such heterozygotes.
RESULTS
The ATM transcript was scanned for mutations in fibroblast and
lymphoblast cell lines derived from an extended series of A-T
patients from 13 countries, all of whom were characterized by the
classical A-T phenotype. The analysis was based on RT-PCR
followed by restriction endonuclease fingerprinting (REF). REF
is a modification of the single-strand conformation polymorph-
ism (SSCP) method, and enables efficient detection of sequence
alterations in DNA fragments up to 2 kb in length (23). Briefly,
after PCR amplification of the target region, multiple restriction
endonuclease digestions are performed prior to SSCP analysis, in
order to increase the sensitivity of the method and enable precise
localization of a sequence alteration within the analyzed frag-
ment. The coding sequence of the ATM transcript, which spans
9168 nucleotides (20), was thus divided into eight partly
overlapping portions of 1.0–1.6 kb, and each one was analyzed
separately. Sequence alterations causing abnormal REF patterns
were located and disclosed by direct sequencing. Mutations
identified in this way were reconfirmed by repeating the RT-PCR
and sequencing, or by testing the presence of the same mutations
in genomic DNA. In compound heterozygotes, the two alleles
were separated by subcloning and individually sequenced. In
some cases, agarose gel electrophoresis showed large deletions in
the ATM transcript manifested as RT-PCR products of reduced
sizes (Fig. 1). The breakpoints of such deletions were delineated
by direct sequencing of these products.
The 44 mutations identified to date in our patient cohort (Table
1 and Fig. 2) include 34 new ones and 10 previously published
ones (19). These mutations were found amongst 55 A-T families:
many are unique to a single family, while others are shared by
several families, most notably the 4 nt deletion, 7517del4, which
is common to six Italian A-T families (Table 1). These families
come from six towns and villages surrounding Naples. According
to this sample, there is a considerable heterogeneity of mutations
in A-T, and most of them are ‘private’. The proportion of
homozygotes in this sample is relatively high due to a high degree
of consanguinity in the populations studied. It should be noted,
however, that apparently homozygous patients from non-consan-
guineous families may in fact be compound heterozygotes with
one allele not expressed or producing an unstable message.
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Figure 2. Distribution of 44 A-T mutations along the open reading frame (stippled box) of the ATM transcript. For large deletions, the symbols mark the locations
of the 5′ breakpoints. Above the line: mutations expected to inactivate the ATM protein. Below the line: mutations which a priori may have a milder nature. By
inference, the latter probably also exert the same effect on the protein.
Table 1. Mutations in the ATM gene in patients with classical A-T
mRNA Predicted Codon8 Patient Ethnic/ Genotype11
sequence protein geographical
change1 alteration origin
Truncations and exon skipping deletions:
9001delAG Truncation 3001 91RD909 Turkish Hmz
8946insA Truncation 2983 AT103LO American Hmz
8307G→A Trp→ter; truncation 2769 AT2SF American Compd Htz
8283delTC Truncation 2762 AT28RM Italian Compd Htz
8269del4032 Truncation 2758 AT12RM Italian Hmz
8269del1503 Del, 50 aa 2758 F-2086 Turkish Compd Htz
GM9587 American Compd Htz
8140C→T Gln→ter; truncation 2714 IARC12/AT3 French Hmz
7883del5 Truncation 2628 ATF104 Japanese Hmz
JCRB316 Japanese Compd Htz
7630del298/7789del1394,5 Truncation 2544 AT4LA Carribean Black Comp Htz
7630del1593 Del, 53 aa 2544 F-2086 Turkish Compd Htz
AT13BER German Compd Htz
7517del4 Truncation 2506 AT43RM10 Italian Hmz
AT59RM10 Italian Hmz
AT22RM10 Italian Hmz
AT57RM10 Italian Compd Htz
AT7RM10 Italian Compd Htz
AT8RM10 Italian Compd Htz
6573del5 Truncation 2192 AT12ABR Australian Compd Htz
6348del1053 Del, 35 aa 2116 IARC15/AT4 French Hmz
6199del1493 Truncation 2067 WG1101 Canadian Hmz
5979del5 Truncation 1994 AT5RM Italian Compd Htz
5712insA Truncation 1905 AT15LA Philippino Compd Htz
5554insC Truncation 1852 F-20799 Turkish Hmz
5539del11 Truncation 1847 AT2RO9 Arab Hmz
5320del3556 Truncation 1774 AT7RM Italian Compd Htz
5320del7 Truncation 1774 AT2SF American Compd Htz
5178del1423 Truncation 1727 AT50RM Italian Compd Htz
4612del1653 Del, 55 aa 1538 ATL105 Japanese Hmz
4437del1753 Truncation 1480 AT29RM Italian Hmz
4110del1273 Truncation 1371 AT2TAN9 Turkish Hmz
3403del1743 Del, 58 aa 1135 F-2095 Turkish Compd Htz
2839del833 Truncation 947 F-20809 Turkish Hmz
AT10TAN9 Turkish Hmz
2467del3723,5 Del, 124 aa 823 AT6LA English/Irish Hmz
2377del903 Del, 30 aa 793 AT21RM9 Italian Hmz
2284delCT Truncation 762 F-1699 Palestinian Arab Hmz
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Table 1.  Continued
2125del1263 Truncation 709 F-20789 Turkish Hmz
2113delT Truncation 705 AT5RM Italian Compd Htz
1563delAG5 Truncation 522 AT8LA9 Swiss/German Hmz
1339C→T Arg→ter; truncation 447 F-20059 Druze Hmz
1240C→T Gln→ter; truncation 414 AT26RM Italian Compd Htz
755delGT Truncation 252 AT24RM Italian Hmz
497del75147 Truncation 166 F-5969 Palestinian-Arab Hmz
30del215 Incorrect 5′ UTR F-303 Bedouine Hmz
initiation
In-frame genomic deletions and insertions:
8578del3 Del, 1 aa 2860 AT3NG Dutch Compd Htz
7636del9 Del, 3 aa 2547 AT2BR Celtic/Irish Hmz
AT1ABR Australian (Irish) Hmz
AT1SF American Compd Htz
7278del65 Del, 2 aa 2427 AT5BI Indian/English Compd Htz
GM5823 English Compd Htz
5319ins9 Ins, 3 aa 1774 251075–008T Finnish Compd Htz
Other base substitutions:
9170G→C ter→Ser ter F-20899 Turkish Hmz
Extension of protein
by 29 amino acids
8711A→G Glu2904Gly 2904 AT41RM Italian Hmz
2T→C Met→Thr 1 AT8BI British Compd Htz
Initiation codon
abolished
1Presented according to the nomenclature proposed by Beaudet & Tsui (41). Nucleotide numbers refer to their positions in the sequence of the ATM transcript (ref.
20; accession number U33841). The first nucleotide of the open reading frame was designated +1.
2Three adjacent exons skipped.
3One exon skipped.
4This allele produces two transcripts, with one or two ajacent exons skipped.
5The same mutation was found in two affected siblings.
6Two exons skipped.
7This transcript is produced by an allele containing a large genomic deletion spanning approximately 85 kb within the ATM gene in Family ISAT 9 (19).
8For deletions, the number of the first codon on the amino terminus side is indicated. Codon numbers are according to the ATM protein sequence published by Savitsky
et al. (20). In each section of the table, the mutations are ordered according to the codon numbers in this column, beginning with the one closest to the carboxyl terminus.
9Consanguineous family.
10All patients are from the same region.
11Genotypic combinations in which the mutation was found. Hmz: homozygote; Compd Htz: compound heterozygote. Each patient represents one family.
This series of 44 A-T mutations is dominated by deletions and
insertions. The smaller ones, of less than 12 nt, reflect identical
sequence alterations in genomic DNA. Deletions spanning larger
segments of the ATM transcript were all found to reflect exon
skipping. This phenomenon usually results from sequence
alterations at splice junctions or within introns, or mutations
within the skipped exons, mainly of the nonsense type (24–28).
One large deletion spans about 7.5 kb of the transcript and
represents a genomic deletion of about 85 kb within the ATM
gene (ref. 19 and unpublished data). Of these deletions and
insertions, 25 are expected to result in frameshifts. Together with
the four nonsense mutations, truncation mutations account for
66% of the total number of mutations in this sample. Seven
in-frame deletions span long segments (30–124 aa) of the protein,
and similarly to the truncation mutations, are expected to have a
severe effect on the protein’s structure. It should be noted that two
base substitutions abolish the translation initiation and termina-
tion codons. The first methionine residue downstream to the
initiator codon is at position 94. The mutation eliminating the
termination codon is expected to result in an extension of the
ATM protein by an additional 29 amino acids. This mutation may
affect the conformation of the nearby PI 3-kinase-like domain.
While the effect of the four small (1–3 aa) in-frame deletions
and insertions on the ATM protein remains to be studied, it should
be noted that one such deletion (8578del3) leads to a loss of a
serine residue at position 2860. This amino acid is part of a
conserved motif within the PI 3-kinase-like domain typical of the
protein family to which ATM is related, and is present in seven
of nine members of this family (Fig. 3). The single missense
mutation identified in this study, which leads to a Glu2904Gly
substitution, results in a nonconservative alteration of another
extremely conserved residue within this domain, which is shared
by all of these proteins (Fig. 3). The patient homozygous for this
mutation, AT41RM, shows the typical clinical A-T phenotype.
Measurement of radioresistant DNA synthesis in the patient’s cell
line revealed a typical A-T response (not shown), demonstrating
that this patient has the classical A-T cellular phenotype.
DISCUSSION
The recently discovered ATM gene is probably involved in a
novel signal transduction system that links DNA damage
surveillance to cell cycle control. A-T mutations affect a variety
of tissues and lead to cancer predisposition. This striking
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Figure 3. Alignment of amino acid sequences within the PI 3-kinase-like domains of the ATM protein and related proteins in various species (see refs 20,21 for details).
One asterisk denotes the serine residue at position 2860 which is deleted in the 8578del3 allele, and two asterisks denote the glutamic acid residue substituted in the
Glu2904Gly allele. tel1: TEL1p of S. cerevisiae; rad3: rad3p of S. pombe; mec1: MEC1p of S. cerevisiae; mei41: mei-41 protein of D. melanogaster. dna-pk: the
catalytic subunit of DNA-dependent protein kinase (DNA-PKCS) in humans; tor1, tor2 and mtor: products of the TOR1 and TOR2 genes in S. cerevisiae and mTOR
(RAFT) in rat.
phenotype together with the existence of ‘partial A-T pheno-
types’ endow the study of ATM mutations with special signifi-
cance.
The large size of the ATM transcript renders its systematic
screening for mutations laborious. The recently developed REF
method (23) appears to offer a particularly suitable tool for this
purpose. This technique was used in our laboratory to identify
ATM as the gene mutated in A-T (19). The power of this method
to efficiently detect sequence variations in large DNA segments
led us to streamline the procedure for a mutation search
throughout the ATM transcript in a larger series of A-T patients.
The ATM gene leaves a great deal of room for mutations: it
encodes a large transcript and contains 65 exons (29). The variety
of mutations identified in this study indeed indicates a rich
mutation repertoire. Despite this wealth of mutations, their
structural characteristics point to a definite bias towards those that
inactivate or eliminate the ATM protein. The nature or distribu-
tion of the genomic deletions among these mutations do not
suggest a special preponderance of the ATM gene for such
mutations, such as that of the dystrophin (30) or steroid sulfatase
(31) genes which are particularly prone to such deletions. Thus,
one would have expected also a strong representation of missense
mutations, which usually constitute a significant portion of the
molecular lesions in many disease genes (24,25). However, only
one such mutation was identified in the present study. Other point
mutations reflected in this series are the nonsense mutations and
those that probably underlie the exon skipping deletions observed
in many patients, again, exerting a severe structural effect on the
ATM protein.
A technical explanation for this bias towards deletions and
insertions could be a greater ability of the REF method to detect
such lesions versus its ability to detect base substitution. Liu and
Sommer (23) have shown, however, that the detection rate of this
method in a sample of 42 point mutations in the factor IX gene
ranged between 88% and 100%, depending on the electrophoresis
conditions. The seven base substitutions detected directly by the
REF method in the present study (Table 1), indicate that such
sequence alterations are detected in our hands as well.
Since the expected result of most of these mutations is complete
inactivation of the protein, this skewed mutation profile might
represent a functional bias related to the studied phenotype, rather
than a structural feature of the ATM gene that lends itself to a
particular mutation mechanism. The classical A-T phenotype
appears to be caused by homozygosity or compound heterozy-
gosity for null alleles, and hence is probably the most severe
expression of defects in the ATM gene. The plethora of missense
mutations expected in the large coding region of this gene is
probably rarely represented in patients with classical A-T, unless
such a mutation results in complete functional inactivation of the
protein. By inference, the only missense mutation identified in
this study, Glu2940Gly, which substitutes a conserved amino acid
at the PI 3-kinase domain and clearly gives rise to a classical A-T
phenotype, points to the importance of this domain for the
biological activity of the ATM protein. The only deletion of a
single amino acid found in this study, 8578del3, is also located in
this region. Mutations in this domain abolish the telomere-
preserving function of the TEL1 protein in Saccharomyces
cerevisiae (32), a protein which shows a particularly high
sequence similarity to ATM (20,21). Another member of the
family of PI 3-kinase-related proteins that includes ATM is the
mammalian FRAP. Mutations in the PI 3-kinase domain abolish
its autophosphorylation ability and biological activity (33). These
observations, together with the mutation shown here, suggest that
this domain in ATM is also likely to include the catalytic site,
which may function as a protein kinase.
Genotype-phenotype relationships associated with the ATM
gene may therefore extend beyond classical A-T. There are
several examples of genes in which different mutations lead to
related but clinically different phenotypes. For example, different
combinations of defective alleles of the ERCC2 gene may result
in xeroderma pigmentosum (group D), Cockayne’s syndrome or
trichothiodystrophy—three diseases with different clinical fea-
tures involving UV sensitivity (34,35). Different mutations in the
CFTR gene may lead to full-fledged cystic fibrosis, or only to
congenital bilateral absence of the vas deferens which is one
feature of this disease (36,37). A particularly interesting example
is the X-linked WASP gene responsible for Wiskott Aldrich
syndrome (WAS), characterized by immunodeficiency, eczema
and thrombocytopenia. Most of the mutations responsible for this
phenotype cause protein truncations; however, certain missense
mutations may result in X-linked thrombocytopenia, which
represents a partial WAS phenotype, while compound heterozy-
gosity for a severe and mild mutation results in females in an
intermediate phenotype (38,39). In a similar manner, genotypic
combinations of mutations with different severities create a
continuous spectrum of phenotypic variation in many metabolic
diseases.
Which phenotypes are most likely to be associated with milder
ATM mutations? Since cerebellar damage is the early and severe
manifestation of A-T, it is reasonable to assume that the
cerebellum might also be affected to some extent in phenotypes
associated with milder ATM mutations. Such phenotypes may
include cerebellar ataxia, either isolated (40) or coupled with
various degrees of immunodeficiency. The latter combination has
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indeed been described, sometimes with chromosomal instability,
and is often designated ‘ataxia without telangiectasia’ (12–16).
Friedman and Weitberg (16) recently suggested a new clinical
category of ‘ataxia with immune deficiency’ that would include
A-T as well as other cases of cerebellar degeneration with
immune deficits. Routine immunological evaluation of patients
with cerebellar disorders may reveal a higher frequency of such
cases than previously estimated. However, in view of the
pleiotropic nature of the ATM gene, the range of phenotypes
associated with various ATM genotypes may be even broader,
and include mild progressive conditions not always defined as
clear clinical entities. Screening for mutations in this gene in such
cases may reveal wider boundaries for the molecular pathology
associated with the ATM gene.
MATERIALS AND METHODS
RT-PCR
Total RNA was extracted from cultured fibroblast or lymphoblast
cells using the Tri-Reagent system (Molecular Research Center,
Cincinnati, OH). Reverse transcription was performed on 2.5 µg of
total RNA, using an oligo(dT) primer and the Superscript II
Reverse Transcriptase (Gibco BRL, Gaithersburg, MD), in 10 µl
reactions containing the buffer recommended by the supplier,
125 U/ml of RNAsin (Promega) and 1 mM dNTPs (Pharmacia).
The reaction products were used as templates for PCR performed
with specific primers. These reactions were carried out in 50 µl
containing 2 U Taq DNA Polymerase (Boehringer Mannheim,
Mannheim, Germany), 200 µM dNTPs, 0.5 µM of each primer,
and one tenth of the RT-PCR products. The products were purified
using the QIA-quick spin system (Qiagen, Hilden, Germany).
Restriction endonuclease fingerprinting
The protocol of Liu and Sommer (23) was followed with slight
modifications. RT-PCR was performed as described above, using
primers defining PCR products of 1.0–1.6 kb. One hundred ng of
amplified DNA was digested separately with five or six restriction
endonucleases in the presence of 0.2 U shrimp alkaline phospha-
tase (United States Biochemicals, Cleveland, OH). Following heat
inactivation at 65C for 10 min, the digestion products correspon-
ding to the same PCR product were pooled, denatured at 96C for
5 min and immediately chilled on ice. Ten ng of this fragment
mixture was labeled in the presence of 6 µCi of [33P]ATP and 1 U
of T4 polynucleotide kinase (New England Biolabs, Beverly, MA)
at 37C for 45 min. Twenty µl of stop solution containing 95%
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol, and 10 mM NaOH were added, and the samples
were boiled for 3 min and quick-chilled on ice. Electrophoresis was
performed in 5.6% polyacrylamide gels in 50 mM Tris-borate, pH
8.3, 1 mM EDTA at constant power of 12 W for 3 h at room
temperature, with a fan directed to the glass plates, keeping them
at 22–24C. The gels were dried and subjected to autoradiography.
A detailed protocol including primer sequences and restriction
enzymes used is available on request.
Direct sequencing of PCR products 
Five hundred ng of PCR products was dried under vacuum,
resuspended in reaction buffer containing the sequencing primer,
and the mixture was boiled and snap-frozen in liquid nitrogen.
The Sequenase II system (Unites States Biochemicals) was used
to carry out the sequencing reaction in the presence of 0.5 µg of
single-strand binding protein (T4 gene 32 protein, United States
Biochemicals). The reaction products were treated with 0.1 µg of
proteinase K at 65C for 15 min, separated on a 6% polyacryl-
amide gel, and visualized by autoradiography.
Sequence accession number 
The nucleotide sequence of the ATM gene transcript was
submitted to the GenBank database under accession no. U33841.
ACKNOWLEDGEMENTS
We are indebted to Drs Steve Sommer and Qiang Liu for technical
information regarding the REF method and to Drs Francis Collins
and Dan Tagle for valuable discussions. We are grateful to Drs
Auli Nuutila and Helena Kaariainen for the cell line
251075–008T. This study was supported by research grants from
the A-T Children’s Project, the A-T Medical Research Founda-
tion, the Thomas Appeal (A-T Medical Research Trust), The
United States-Israel Binational Science Foundation, Consiglio
Nazionale Ricerche Progetto Finalizzato Applicazioni Cliniche
Ricerca Oncologica, and the National Institute of Neurological
Disorders and Stroke (NS31763). This work was carried out in
partial fulfillment of the requirements for the Ph.D. degree to S.G.
REFERENCES
1. Harnden, D.G. (1994) The nature of ataxia-telangiectasia: problems and
perspectives. Int. J. Radiat. Biol. 66, S13-S19.
2. Taylor, A.M.R., Byrd, P.J., McConville, C.M. and Thacker, S. (1994) Genetic
and cellular features of ataxia telangiectasia. Int. J. Radiat. Biol. 65, 65–70.
3. Shiloh, Y. (1995) Ataxia-telangiectasia: Closer to unraveling the mystery.
Eur. J. Hum. Genet. 3, 116–138.
4. Houldsworth, J. and Lavin, M.F. (1980) Effect of ionizing radiation on DNA
synthesis in ataxia telangiectasia cells. Nucleic Acids Res. 8, 3709–3720.
5. Beamish, H. and Lavin, M.F. (1994) Radiosensitivity in ataxia-telangiectasia:
Anomalies in radiation-induced cell cycle delay. Int. J. Radiat. Biol. 65,
175–184.
6. Kastan, M.B., Zhan, Q., El-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V.,
Plunkett, B.S., Vogelstein, B., Fornace, A.J. (1992) A mammalian cell cycle
checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telan-
giectasia. Cell 71, 587–597.
7. Khanna, K.K. and Lavin, M.F. (1993) Ionizing radiation and UV induction of
p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8,
3307–3312.
8. Fiorilli, M., Antonelli, A., Russo, G., Crescenzi, M., Carbonari, M. &
Petrinelli, P. (1985) Variant of ataxia-telangiectasia with low-level radiosensi-
tivity. Hum. Genet. 70, 274–277.
9. Taylor, A.M.R., Flude, E., Laher, B., Stacey, M., McKay, E., Watt, J., Green,
S.H. and Harding, A.E. (1987) Variant forms of ataxia telangiectasia. J. Med.
Genet. 24, 669–677.
10. Ziv, Y., Amiel, A., Jaspers, N.G.J., Berkel, A.I. and Shiloh, Y. (1989) Ataxia
telangiectasia: a variant with altered in vitro phenotype of fibroblast cells.
Mutation Res. 210, 211–219.
11. Chessa, L., Petrinelli, P., Antonelli, A., Fiorilli, M., Elli, L., Marcucci, L.,
Federico, A. and Gandini, E. (1992) Heterogeneity in ataxia telangiectasia:
classical phenotype associated with intermediate cellular radiosensitivity.
Am. J. Med. Genet. 42, 741–746.
12. Ying, K.L. and Decoteau, W.E. (1983) Cytogenetic anomalies in a patient
with ataxia, immune deficiency, and high alpha-fetoprotein in the absence of
telangiectasia. Cancer Genet. Cytogenet. 4, 311–317.
13. Byrne, E., Hallpike, J.F., Manson, J.I., Sutherland G.R. and Thong, Y.H.
(1984) Ataxia-without-telangiectasia. J. Neurol. Sci. 66, 307–317.
14. Aicardi J, Barbosa C., Andermann, E., Andermann, F., Morcos, R., Ghanem,
Q., Fukuyama, Y., Awaya, Y., and Moe, P. (1988) Ataxia-ocular motor
apraxia: A syndrome mimicking ataxia-telangiectasia. Ann. Neurol. 24,
497–502.








Nucleic Acids Research, 1994, Vol. 22, No. 1Human Molecular Genetics, 1996, Vol. 5, No. 4 439
15. Maserati, E., Ottolin, A., Veggiotti, P., Lanzi, G. and Pasquali, F. (1988)
Ataxia-without-telangiectasia in two sisters with rearrangements of chromo-
somes 7 and 14. Clin. Genet. 34, 283–287.
16. Friedman, J.H. and Weitberg, A. (1993) Ataxia without telangiectasia.
Movement Disorders 8, 223–226.
17. Weemaes, C.M.R., Smeets, D.F.C.M. and Burgt C.J.A.M. (1994) Nijmegen
breakage syndrome: A progress report. Int. J. Radiat. Biol. 66, S185-S188.
18. Gatti, R.A., Berkel, I., Boder, E., Braedt, G., Charmley, P., Concannon, P.,
Foroud, T., Jaspers, N.G.J., Lange, K., Lathrop, G.M., Leppert, M.,
Nakamura, Y., O′Connel, P., Paterson, M., Salser, W., Sanal,, O., Silver, J.,
Sparkes, R.S., Susi, E., Weeks, D.E., Wei, S., White, R. and Yoder, F.
Localization of an ataxia-telangiectasia gene to chromosome 11q22–23.
Nature 336, 577–580.
19. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L.,
Tagle, D.A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman,
M., Harnik, R., Patanjali, S.R., Simmons, A., Clines, G.A., Sartiel, A., Gatti,
R.A., Chessa, L., Sanal, O., Lavin, M.F., Jaspers, N.G.J., Taylor, A.M.R.,
Arlett, C.F., Miki, T., Weissman, S., Lovett, M., Collins, F.S. and Shiloh, Y.
(1995) A single ataxia telangiectasia gene with a product similar to PI-3
kinase. Science 268, 1749–1753.
20. Savitsky, K., Sfez, S., Tagle, D., Ziv, Y., Sartiel, A., Collins, F.S., Shiloh, Y.
and Rotman, G. (1995) The complete sequence of the coding region of the
ATM gene reveals similarity to cell cycle regulators in different species. Hum.
Mol. Genet. 4, 2025–2032.
21. Zakian, V.A. (1995) ATM-related genes: What do they tell us about functions
of the human gene? Cell 82, 685–687.
22. Gottlieb, T.M. and Jackson, S.P. (1994) Protein kinases and DNA damage.
Trends Biochem. Sci. 19, 500–503.
23. Liu, Q. and Sommer, S.S. (1995) Restriction endonuclease fingerprinting
(REF): a sensitive method for screening mutations in long, contiguous
segments of DNA. BioTechniques 18, 470–477.
24. Cooper, D.N. and Krawczak, M. (1993) Human gene mutation. BIOS
Scientific Publishers, London.
25. Sommer, S. (1995) Recent human germ-line mutation: Inferences from
patients with hemophilia B. Trends Genet. 11, 141–147.
26. Steingrimsdottir, H., Rowley, G., Dorado, G., Cole, J., and Lehmann, A.R.
(1992) Mutations which alter splicing in the human hypoxanthine-guanine
phosphoribosyltransferase gene. Nucleic Acids Res. 6, 1201–1208.
27. Gibson, R.A., Hajianpour, A., Murer-Orlando, M., Buchwald, M., and
Mathew, C.G. (1993) A nonsense mutation and exon skipping in the Fanconi
anaemia group C gene. Hum. Mol. Genet. 2, 797–799.
28. Dietz, H.C., and Kendzior, R.J., Jr. (1994) Maintenance of an open reading
frame as an additional level of scrutiny during splice site selection. Nature
Genet. 8, 183–188.
29. Uziel, T., Savitsky, K., Platzer, M., Ziv, Y., Helbitz, T., Nehls, M., Boehm, T.,
Rosenthal, A., Shiloh, Y. and Rotman, G. (1996) Genomic organization of the
ATM gene. Genomics, in press.
30. Anderson, M.S. and Kunkel, L.M. (1992) The molecular and biochemical
basis of Duchenne muscular dystrophy. Trends Biochem. Sci. 17, 289–292.
31. Ballabio, A., Carrozzo, R., Parenti, G., Gil, A., Zollo, M., Persico, M.G.,
Gillard, E., Affara, N., Yates, J., Fergouson-Smith, M.A., Frants, R.R.,
Eriksson, A.W. and Andria, G. (1989) Molecular heterogeneity of steroid
sulfatase deficiency: a multicenter study on 57 unrelated patients, at DNA and
protein levels. Genomics 4, 36–40.
32. Greenwell, P.W., Kronmal, S.L., Porter, S.E., Gassenhuber, J., Obermaier, B.
and Petes, T.D. (1995) TEL1, a gene involved in controlling telomere length
in Saccharomyces cerevisiae, is homologous to the human ataxia telangiecta-
sia (ATM) gene. Cell 82, 823–829.
33. Brown, E.J., Beal, P.A., Curtis, T. Keith, Chen, J., Bum Shin, T., and
Schreiber, S.L. (1995) Control of p70 S6 kinase by kinase activity of FRAP in
vivo. Nature 377, 441–446.
34. Broughton, B.C., Steingrimsdottir, H., Weber, C.A. and Lehmann, A.R.
(1994) Mutations in the xeroderma pigmentosum group D DNA repair/tran-
scription gene in patients with trichothiodystrophy. Nature Genet. 7,
189–194.
35. Broughton, B.C., Thompson, A.F., Harcourt, S.A., Vermeulen, W., Hoeij-
makers, J.H., Botta, E., Stefanini, M., King, M.D., Weber, C.A., Cole, J.,
Arlett, C.F. and Lehmann, A.R. (1995) Molecular and cellular analysis of the
DNA repair defect in a patient in xeroderma pigmentosum group D who has
the clinical features of xeroderma pigmentosum and Cockayne’s syndrome.
Am. J. Hum. Genet. 56, 167–174.
36. Chillon, M., Casals, T., Mercier, B., Bassas, L., Lissens, W., Silber, S. et al.
(1995) Mutations in the cystic fibrosis gene in patients with congenital
absence of the vas deferens. N. Engl. J. Med. 332, 1475–1480.
37. Jarvi, K., Zielenski, J., Wilschanski, M., Durie, P., Buckspan, M., Tullis, E.,
Markiewicz, D. and Tsui, L.-C. (1995) Cystic fibrosis transmembrane
conductance regulator and obstructive azoospermia. Lancet 345, 1578.
38. Kolluri, R., Shehabeldin A., Peacocke, M., Lamhonwah, A.-M., teichert-Ku-
liszewska, K., Weissman, S.M. and Siminovitch, K.A. (1995) Identification
of WASP mutations in patients with Wiskott-Aldrich syndrome and isolated
thrombocytopenia reveals allelic heterogeneity at the WAS locus. Hum. Mol.
Genet. 4, 1119–1126.
39. Derry, J.M.J., Kerns, J.A., Weinberg, K.I., Ochs, H.D., Volpini, V., Estivill, X.,
Walker, A.P. and Francke, U. (1995) WASP gene mutations in Wiskott-
Aldrich syndrome and X-linked thrombocytopenia. Hum. Mol. Genet. 4,
1127–1135.
40. Harding, A.E. (1993) Clinical features and classification of inherited ataxias.
Adv. Neurol. 61, 1–14.
41. Beaudet, A.L. and Tsui, L.-C. (1993) A suggested nomenclature for
designating mutations. Hum. Mutat. 2, 245–248.
 at Institute of Social Studies on June 5, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
